New Mayo clinic study shows no benefit from widely accepted treatment for Graves' ophthalmopathy

September 05, 2001

ROCHESTER, MINN. -- A new Mayo Clinic study of patients who have mild or moderately severe Graves' ophthalmopathy, also known as Graves' eye disease or thyroid eye disease, demonstrated no benefit from orbital radiotherapy (radiation therapy to the area containing the eyeball), which has been widely used to treat the disease.

The study appears in the September issue of Ophthalmology, the journal of the American Academy of Ophthalmology.

"The effectiveness of this treatment, which has been widely used for 80 years, has never been convincingly established," says Colum Gorman, M.D., Ph. D., a Mayo Clinic endocrinologist and specialist in Graves' disease.

The researchers designed the study so that neither the patient nor those who appraised the treatment response via extremely precise measurements knew which eye had been treated. They learned that there was no difference between treated and untreated eyes after either three or six months. The researchers then studied whether treatment earlier or six months later in the course of the disease made a difference, and they found none.

"Because this treatment is still in wide use, is expensive and is not without risk, it is our belief that it should not be used for patients with mild or moderately severe ophthalmopathy," says Dr. Gorman.

The researchers did not study patients with very severe ophthalmopathy that has damaged the optic nerve. Thus, they have no data on the effectiveness of orbital radiotherapy for those patients.

"It is important to understand the entire disease process and how it affects the whole person," says Dr. Gorman. "Graves' disease is a naturally remitting condition, and over a period of time many of the symptoms, including the eyes, may improve. It is our belief that this tendency to natural remission, together with the imprecision of measurements used in most previous studies, has allowed the perception to persist that the treatment is effective."

As patients with Graves' ophthalmopathy decide on what treatment is best for them, Dr. Gorman emphasizes the importance of developing a coordinated approach in which the patient, an endocrinologist and ophthalmologist work together as a team to define the best action plan. Other forms of readily available treatment include the use of oral corticosteroids, orbital decompression, eye muscle surgery and eyelid surgery.

Graves' disease is a form of hyperthyroidism in which too much thyroid hormone is present in the body, causing an increase in the body's metabolism. Graves' disease most often affects women between the ages of 20 to 60 years. With modern treatment, it is not considered life-threatening. Graves' ophthalmopathy is less common, causing problems in approximately three to five percent of the persons who are diagnosed with Graves' disease. Graves' ophthalmopathy is characterized by bulging eyes or red and swollen eyes; excessive tearing; widening of the space between upper and lower eyelids; and light sensitivity, blurry or double vision, inflammation or restricted eye movements.
-end-
Lisa Copeland
507-284-5005 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

Mayo Clinic

Related Radiation Therapy Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

New approach for calculating radiation dosimetry allows for individualized therapy
Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan.

Developing microbeam radiation therapy (MRT) for inoperable cancer
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

Travel considerations specified for 177Lu-DOTATATE radiation therapy patients
Researchers and patient advocates have addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in the April issue of The Journal of Nuclear Medicine.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

AI can jump-start radiation therapy for cancer patients
Artificial intelligence can help cancer patients start their radiation therapy sooner -- and thereby decrease the odds of the cancer spreading -- by instantly translating complex clinical data into an optimal plan of attack.

Towards safer, more effective cancer radiation therapy using X-rays and nanoparticles
X-rays could be tuned to deliver a more effective punch that destroys cancer cells and not harm the body.

Radiation therapy effective against deadly heart rhythm
A single high dose of radiation aimed at the heart significantly reduces episodes of a potentially deadly rapid heart rhythm, according to results of a phase one/two study at Washington University School of Medicine in St.

New mathematical model can improve radiation therapy of brain tumours
Researchers have developed a new model to optimize radiation therapy and significantly increase the number of tumor cells killed during treatment.

Using artificial intelligence to deliver personalized radiation therapy
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to personalize the dose of radiation therapy used to treat cancer patients.

Read More: Radiation Therapy News and Radiation Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.